Opinion|Videos|July 24, 2024
Insights from the TROPION-Lung05 Trial at ASCO 2024
Author(s)Jason Porter, MD
Jason Porter, MD, analyzes the TROPION-Lung05 trial investigating Dato-DXd in non-small cell lung cancer patients with brain metastases, emphasizing crucial insights from this pivotal study.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Discuss the data that was presented at the ASCO 2024 on intracranial overall response rate in the TROPION-Lung05 trial with Dato-DXd in patients with brain metastasis from NSCLC.
- What are your key takeaways from this study and how will this impact the treatment of patients with brain metastasis from NSCLC?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Walcker Named President of Cardinal’s The Specialty Alliance, With Strengths in GI, Urology
2
5 Questions Dermatology Patients May Have About Newly-Approved Bemotrizinol
3
Venetoclax-Obinutuzumab Tops Acalabrutinib in First-Line CLL
4
Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer
5